Genetic disorders occur due to alterations in the primary genetic material—deoxyribonucleic acid (DNA)—of an organism.
The Phase 1/2 trial is a first-in-human, open-label, multi-national study designed to evaluate the safety, tolerability, and efficacy of TSRA-196 in adults with AATD. Trial participants will receive a ...
Scientists and physicians can better assess precision genome editing technology using a new method made public today by St.
In a new study, the researchers have shown that the CRISPR–Cas3 system can induce reliable, extensive deletions of the ...
Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA ...
Find how Circularization for High-throughput Analysis of Nuclease Genome-wide Effects by Sequencing Base Editors ...
In conjunction with the strategic evolution, the Company appointed Jian Irish, Ph.D., M.B.A., as Chief Executive Officer. Based on a revised capital allocation strategy, the Company extended its ...
CHANGE-seq-BE was developed to enable scientists to better understand base editors, an important class of CRISPR precise genome editors.
Back in 2016, a group of researchers led by Harvard’s David Liu, PhD, published a paper in Nature that reported the development of base editing. Base editing, they wrote, is “a new approach to genome ...
Researchers restored hearing in preclinical mouse models with a specific form of inherited deafness called DFNA50 caused by mutations in microRNA, by using a novel in vivo CRISPR genome editing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback